CY1121414T1 - Παρασκευη ιικου φορεα - Google Patents

Παρασκευη ιικου φορεα

Info

Publication number
CY1121414T1
CY1121414T1 CY20181100533T CY181100533T CY1121414T1 CY 1121414 T1 CY1121414 T1 CY 1121414T1 CY 20181100533 T CY20181100533 T CY 20181100533T CY 181100533 T CY181100533 T CY 181100533T CY 1121414 T1 CY1121414 T1 CY 1121414T1
Authority
CY
Cyprus
Prior art keywords
virus
modified
cell
operator
production
Prior art date
Application number
CY20181100533T
Other languages
Greek (el)
English (en)
Inventor
Paul Michael Howley
Liang Liu
Original Assignee
Sementis Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013904242A external-priority patent/AU2013904242A0/en
Application filed by Sementis Limited filed Critical Sementis Limited
Publication of CY1121414T1 publication Critical patent/CY1121414T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24151Methods of production or purification of viral material
    • C12N2710/24152Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CY20181100533T 2013-11-01 2018-05-22 Παρασκευη ιικου φορεα CY1121414T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2013904242A AU2013904242A0 (en) 2013-11-01 Viral vector manufacture
AU2014900370A AU2014900370A0 (en) 2014-02-07 Orthopox vectors and propagation
PCT/AU2014/050330 WO2015061858A1 (en) 2013-11-01 2014-11-03 Viral vector manufacture

Publications (1)

Publication Number Publication Date
CY1121414T1 true CY1121414T1 (el) 2020-05-29

Family

ID=53003022

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100533T CY1121414T1 (el) 2013-11-01 2018-05-22 Παρασκευη ιικου φορεα

Country Status (25)

Country Link
US (2) US10544397B2 (https=)
EP (2) EP3375882B1 (https=)
JP (2) JP6682443B2 (https=)
KR (1) KR102047030B1 (https=)
CN (1) CN106255758B (https=)
AU (1) AU2014344738B2 (https=)
CA (1) CA2931518C (https=)
CY (1) CY1121414T1 (https=)
DK (2) DK3063278T3 (https=)
ES (1) ES2670034T3 (https=)
HR (1) HRP20180789T1 (https=)
HU (1) HUE037718T2 (https=)
IL (1) IL245363B (https=)
LT (1) LT3063278T (https=)
NO (1) NO3063278T3 (https=)
NZ (1) NZ720241A (https=)
PL (1) PL3063278T3 (https=)
PT (1) PT3063278T (https=)
RS (1) RS57290B1 (https=)
RU (1) RU2658487C2 (https=)
SG (1) SG11201603919XA (https=)
SI (1) SI3063278T1 (https=)
SM (1) SMT201800267T1 (https=)
TR (1) TR201807128T4 (https=)
WO (1) WO2015061858A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL264893B (en) * 2016-08-19 2022-08-01 Sementis Ltd Vaccines for viruses
JP2018081568A (ja) * 2016-11-17 2018-05-24 グローリー株式会社 紙幣収納装置および紙幣処理機
IL295154A (en) * 2020-01-28 2022-09-01 Lonza Walkersville Inc Methods for determining viral titer
EP4547689A1 (en) * 2022-06-30 2025-05-07 Bavarian Nordic A/S Mammalian cell line for the production of modified vaccinia virus ankara (mva)
WO2024064608A2 (en) * 2022-09-20 2024-03-28 Intergalactic Therapeutics, Inc. Best1 vectors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2604183B1 (fr) 1986-09-23 1988-12-30 Transgene Sa Sequence d'adn, vecteurs, virus recombinants et procede mettant en oeuvre des virus de la vaccine recombinants capables de se multiplier dans les cellules cho
ATE298370T1 (de) 1994-04-29 2005-07-15 Baxter Healthcare Sa Rekombinante poxviren mit fremdenpolynukleotiden in wichtigen regionen
WO2004015118A1 (en) * 2002-08-07 2004-02-19 Bavarian Nordic A/S Vaccinia virus host range genes to increase the titer of avipoxviruses
FR2884255B1 (fr) * 2005-04-11 2010-11-05 Vivalis Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe
CA2658301A1 (en) * 2006-08-04 2008-02-07 Dublin City University A method of producing recombinant biological products

Also Published As

Publication number Publication date
CN106255758A (zh) 2016-12-21
ES2670034T3 (es) 2018-05-29
WO2015061858A1 (en) 2015-05-07
AU2014344738B2 (en) 2019-03-21
DK3063278T3 (en) 2018-06-06
EP3063278B1 (en) 2018-02-28
PT3063278T (pt) 2018-05-25
KR102047030B1 (ko) 2019-11-20
RU2016121425A (ru) 2017-12-04
JP6682443B2 (ja) 2020-04-15
US10544397B2 (en) 2020-01-28
IL245363B (en) 2020-01-30
DK3375882T3 (da) 2019-12-16
HUE037718T2 (hu) 2018-09-28
JP2020039340A (ja) 2020-03-19
IL245363A0 (en) 2016-06-30
EP3375882A1 (en) 2018-09-19
SG11201603919XA (en) 2016-07-28
PL3063278T3 (pl) 2018-08-31
AU2014344738A1 (en) 2016-06-09
US20170029784A1 (en) 2017-02-02
SMT201800267T1 (it) 2018-07-17
NO3063278T3 (https=) 2018-07-28
EP3375882B1 (en) 2019-10-16
NZ720241A (en) 2019-10-25
KR20160079868A (ko) 2016-07-06
HRP20180789T1 (hr) 2018-09-07
RU2658487C2 (ru) 2018-06-21
CA2931518C (en) 2021-03-09
EP3063278A4 (en) 2017-04-12
LT3063278T (lt) 2018-07-10
HK1223395A1 (en) 2017-07-28
SI3063278T1 (sl) 2019-04-30
JP2016534755A (ja) 2016-11-10
US20200190482A1 (en) 2020-06-18
RS57290B1 (sr) 2018-08-31
EP3063278A1 (en) 2016-09-07
CA2931518A1 (en) 2015-05-07
TR201807128T4 (tr) 2018-06-21
CN106255758B (zh) 2020-06-23

Similar Documents

Publication Publication Date Title
CY1121414T1 (el) Παρασκευη ιικου φορεα
CY1122833T1 (el) Ογκολυτικος αδενοϊος που κωδικοποιει μια πρωτεϊνη β7
PH12018501159A1 (en) Composition and methods for immunooncology
MX2020009401A (es) Ligadores de nucleótidos modificados.
MX389789B (es) Moléculas del receptor de envolvimiento quimérico.
PH12019502171A1 (en) Composition and methods for immunooncology
UY34820A (es) Compuestos tipo pirrolo-pirrolidinona
PH12017500858A1 (en) Mocrocyclic peptides useful as immunomodulators
EP4477741A3 (en) Oligosaccharide production
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
CY1125996T1 (el) Ρυθμιστες της δραστικοτητας του συμπληρωματος
MX380772B (es) 3-epimerasa.
UY34824A (es) Nucleósidos de espirooxetano de uracilo
PE20151433A1 (es) Nucleosidos sustituidos, nucleotidos y analogos de los mismos
BR112016029076A2 (pt) modulação de atividade de complemento
MX2015011529A (es) Reordenamiento del virus de infuenza b.
SK500072021U1 (sk) Prírodný vanilín
BR112018005940A2 (pt) métodos de garantia da qualidade molecular para uso em sequenciamento
PH12018500155A1 (en) Recombinant orf virus vector
PH12016500683B1 (en) Synthetic route to 2`-deoxy-2`,2`-difluorotetrahydrouridines
MA42373A (fr) Procede de liaison de dioxyde de carbone
TR201902604T4 (tr) Fi̇berglas kompozi̇ti̇, bunun cam fi̇beri̇ ve bunun kompozi̇t materyali̇.
BR112017020896A2 (pt) variantes de protoxina-ii e métodos de uso
MX2021013879A (es) Variantes de lipasa y polinucleotidos que las codifican.
BR112016027455A2 (pt) moduladores ppar